Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 10/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 10/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 7/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 7/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561668 | 0.82 | FDFT1 (0.50) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL30930670 | 0.81 | SMN1; SMN2 (0.50) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL932147 | 0.81 | SMN1; SMN2 (0.50) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL17673062 | 0.80 | MAPT (0.65) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL1736045 | 0.78 | MEN1 (0.46) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL20576296 | 0.78 | MEN1 (0.50) | FDFT1KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL19776335 | 0.77 | NPSR1 (0.58) | KDM4ENPC1RAB9AALDH1A1LMNA | |
| SCHEMBL7930779 | 0.77 | HDAC1 (0.48) | FDFT1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL30930679 | 0.75 | KCNQ3 (0.67) | KDM4ENPC1RAB9AALDH1A1KCNQ3 | |
| SCHEMBL31329104 | 0.75 | NPC1 (0.56) | NPC1RAB9AALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, PF4 | FDFT1 4832/4885KDM4E 1367/4885NPC1 2459/4885 |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | FDFT1 4780/4885KDM4E 1720/4885NPC1 1939/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | FDFT1 4797/4885KDM4E 1806/4885NPC1 2049/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | FDFT1 4780/4885KDM4E 1720/4885NPC1 1939/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | FDFT1 3803/4885KDM4E 3061/4885NPC1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.